Mark Ragosa, CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc (KNSA), sold 41,134 shares at $23.10 ($950K) on 2025-03-19, disclosed to the SEC on 2025-03-19.
Scheduled sale ($950k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.61 | 448 | $10K | 1.1% |
| 2 | $23.10 | 11,464 | $265K | 27.9% |
| 3 | $23.10 | 11,464 | $265K | 27.9% |
| 4 | $23.10 | 8,879 | $205K | 21.6% |
| 5 | $23.10 | 8,879 | $205K | 21.6% |
| Total | $23.09 avg | 41,134 |
| $950K |
| 100% |
| Filing → |
| KNSA | SELL | 2026-01-09 | $503K | — | Filing → |
| KNSA | SELL | 2025-12-10 | $3.6M | — | Filing → |
| KNSA | SELL | 2025-11-14 | $815K | — | Filing → |